The Effect of Informative Letters on the Prescription and Receipt of Seroquel
- Conditions
- Health ExpendituresEconomicsFraudCenters for Medicare and Medicaid Services (U.S.)Delivery of Health Care
- Registration Number
- NCT02467933
- Lead Sponsor
- Abdul Latif Jameel Poverty Action Lab
- Brief Summary
Abusive prescribing exposes patients to unnecessary health risks and results in wasteful public expenditures. This study will evaluate an innovative approach to fighting abusive prescription: sending letters to suspected inappropriate prescribers warning them that they are outliers compared to their peers and have been flagged for review. The study will target high prescribers of Seroquel (Quetiapine), an atypical antipsychotic. Using claims data, the investigators will assess the effect of the letters on prescribing of Seroquel, receipt of Seroquel by patients, substitution behavior by prescribers and patients, and health outcomes of patients.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 5055
- General care practitioner
- Outlier with respect to the count of Seroquel prescription drug treatments relative to peer group of prescribers in 2013 and 2014
- Outlier with respect to the count of Seroquel 30-day equivalent prescription drug treatments relative to peer group of prescribers in 2013 and 2014
- Deceased
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Primary Outcome Measures
Name Time Method 30-day equivalent prescribing of Seroquel treatments 9 months The prescribing of Seroquel over the 9 months following the initial sending of the letters. Prescribing is defined as the total "days supply" of Seroquel attributed to the prescriber, expressed in "30-day equivalents" i.e. divided by 30.
- Secondary Outcome Measures
Name Time Method 30-day equivalent prescribing of Seroquel treatments 1 year